You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameHuman Serum Albumin
Accession NumberDB00062  (BIOD00059, BTD00059)
Typebiotech
Groupsapproved
Description

Human serum albumin isolated from expired blood plasma

Protein structureDb00062
Protein chemical formulaC2936H4624N786O889S41
Protein average weight66472.2000
Sequences
> Human Serum Albumin Sequence
MKWVTFISLLFLFSSAYSRGVFRRDAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPF
EDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEP
ERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLF
FAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAV
ARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLK
ECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYAR
RHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFE
QLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVV
LNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTL
SEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLV
AASQAALGL
Download FASTA Format
Synonyms
SynonymLanguageCode
Serum albumin precursorNot AvailableNot Available
SaltsNot Available
Brand names
NameCompany
AlbuteinAlpha Therapeutic Corp
Brand mixturesNot Available
Categories
CAS number9048-49-1
Taxonomy
KingdomOrganic Compounds
SuperclassOrganic Acids
ClassCarboxylic Acids and Derivatives
SubclassAmino Acids, Peptides, and Analogues
Direct parentPeptides
Alternative parentsNot Available
SubstituentsNot Available
Classification descriptionNot Available
Pharmacology
IndicationFor treatment of severe blood loss, hypervolemia, hypoproteinemia
PharmacodynamicsRegulates the colloidal osmotic pressure of blood. It is used to increase the circulating plasma volume, thereby reducing hemoconcentrtion and blood viscosity. Also used as a transport protein that binds naturally occurring, therapeutic and toxic materials in circulation.
Mechanism of actionActs as a high molecular weight, very soluble osmolyte
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
Metabolism
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionIntravenous
Prices
Unit descriptionCostUnit
Buminate 25% iv solution2.22USDml
Albumin 25% iv solution1.97USDml
Albutein 25% vial1.32USDml
Buminate 5% iv solution0.44USDml
Albutein 5% iv solution0.43USDml
Albumin (human) 5% iv solution0.3USDml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
Stateliquid
Experimental Properties
PropertyValueSource
melting point62 °CFlora, K. et al., Biophys J. 75:1084-1096 (1998)
hydrophobicity-0.395Not Available
isoelectric point5.67Not Available
References
Synthesis Reference

Robert A. Tenold, “Preparing essentially monomeric normal human serum albumin.” U.S. Patent USRE0362590, issued July, 1976.

USRE0362590
General ReferenceNot Available
External Links
ResourceLink
UniProtP02768
GenbankM12523
PharmGKBPA164743293
Drug Product Database427675
RxListhttp://www.rxlist.com/cgi/generic3/albumin.htm
ATC CodesNot Available
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Interactions
Drug InteractionsSearched, but no interactions found.
Food InteractionsNot Available

Targets

1. Apolipoprotein E

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Apolipoprotein E P02649 Details

References:

  1. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K: Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther. 2006 Jun;317(3):1246-53. Epub 2006 Mar 22. Pubmed
  2. Yamashita T, Kawashima S, Hirase T, Shinohara M, Takaya T, Sasaki N, Takeda M, Tawa H, Inoue N, Hirata K, Yokoyama M: Xenogenic macrophage immunization reduces atherosclerosis in apolipoprotein E knockout mice. Am J Physiol Cell Physiol. 2007 Sep;293(3):C865-73. Epub 2007 Jun 6. Pubmed
  3. Yuan ZY, Liu Y, Kishimoto C, Shioji K, Yokode M, Liu ZQ: [The Fc region of immunoglobulin suppresses atherosclerosis in apolipoprotein E knockout mice] Zhonghua Yi Xue Za Zhi. 2003 Mar 25;83(6):489-93. Pubmed
  4. Mojzisova H, Bonneau S, Vever-Bizet C, Brault D: The pH-dependent distribution of the photosensitizer chlorin e6 among plasma proteins and membranes: a physico-chemical approach. Biochim Biophys Acta. 2007 Feb;1768(2):366-74. Epub 2006 Oct 25. Pubmed
  5. Yuan Z, Kishimoto C, Sano H, Shioji K, Xu Y, Yokode M: Immunoglobulin treatment suppresses atherosclerosis in apolipoprotein E-deficient mice via the Fc portion. Am J Physiol Heart Circ Physiol. 2003 Aug;285(2):H899-906. Pubmed

2. Serum amyloid A-1 protein

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Serum amyloid A-1 protein P0DJI8 Details

References:

  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. Pubmed
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. Pubmed

3. Protein AMBP

Kind: protein

Organism: Human

Pharmacological action: unknown

Components

Name UniProt ID Details
Protein AMBP P02760 Details

References:

  1. Sala A, Campagnoli M, Perani E, Romano A, Labo S, Monzani E, Minchiotti L, Galliano M: Human alpha-1-microglobulin is covalently bound to kynurenine-derived chromophores. J Biol Chem. 2004 Dec 3;279(49):51033-41. Epub 2004 Sep 27. Pubmed

Enzymes

1. Cytochrome P450 2C9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Cytochrome P450 2C9 P11712 Details

References:

  1. Zhou Q, Matsumoto S, Ding LR, Fischer NE, Inaba T: The comparative interaction of human and bovine serum albumins with CYP2C9 in human liver microsomes. Life Sci. 2004 Sep 17;75(18):2145-55. Pubmed]

2. Myeloperoxidase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Myeloperoxidase P05164 Details

References:

  1. Salavej P, Spalteholz H, Arnhold J: Modification of amino acid residues in human serum albumin by myeloperoxidase. Free Radic Biol Med. 2006 Feb 1;40(3):516-25. Epub 2005 Nov 9. Pubmed
  2. Senthilmohan R, Kettle AJ: Bromination and chlorination reactions of myeloperoxidase at physiological concentrations of bromide and chloride. Arch Biochem Biophys. 2006 Jan 15;445(2):235-44. Epub 2005 Aug 3. Pubmed

3. UDP-glucuronosyltransferase 1-9

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inducer

Components

Name UniProt ID Details
UDP-glucuronosyltransferase 1-9 O60656 Details

References:

  1. Rowland A, Knights KM, Mackenzie PI, Miners JO: The “albumin effect” and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos. 2008 Jun;36(6):1056-62. Epub 2008 Mar 24. Pubmed

Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 13, 2013 10:49